JP6419706B2 - ミニプロモーターカセットを含むレトロウイルスベクター - Google Patents

ミニプロモーターカセットを含むレトロウイルスベクター Download PDF

Info

Publication number
JP6419706B2
JP6419706B2 JP2015539817A JP2015539817A JP6419706B2 JP 6419706 B2 JP6419706 B2 JP 6419706B2 JP 2015539817 A JP2015539817 A JP 2015539817A JP 2015539817 A JP2015539817 A JP 2015539817A JP 6419706 B2 JP6419706 B2 JP 6419706B2
Authority
JP
Japan
Prior art keywords
promoter
retrovirus
cells
pac3
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015539817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533510A5 (cg-RX-API-DMAC7.html
JP2015533510A (ja
Inventor
イー． グリューバー，ハリー
イー． グリューバー，ハリー
ジェイ． ジョリー，ダグラス
ジェイ． ジョリー，ダグラス
エイチ． リン，エイミー
エイチ． リン，エイミー
アール． ログ，クリストファー
アール． ログ，クリストファー
カサハラ，ノリユキ
Original Assignee
トカジェン インコーポレーテッド
トカジェン インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トカジェン インコーポレーテッド, トカジェン インコーポレーテッド filed Critical トカジェン インコーポレーテッド
Publication of JP2015533510A publication Critical patent/JP2015533510A/ja
Publication of JP2015533510A5 publication Critical patent/JP2015533510A5/ja
Application granted granted Critical
Publication of JP6419706B2 publication Critical patent/JP6419706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2015539817A 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター Expired - Fee Related JP6419706B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261718610P 2012-10-25 2012-10-25
US61/718,610 2012-10-25
PCT/US2013/066709 WO2014066700A1 (en) 2012-10-25 2013-10-24 Retroviral vector with mini-promoter cassette

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018128726A Division JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター

Publications (3)

Publication Number Publication Date
JP2015533510A JP2015533510A (ja) 2015-11-26
JP2015533510A5 JP2015533510A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6419706B2 true JP6419706B2 (ja) 2018-11-07

Family

ID=50545284

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015539817A Expired - Fee Related JP6419706B2 (ja) 2012-10-25 2013-10-24 ミニプロモーターカセットを含むレトロウイルスベクター
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018128726A Pending JP2018183155A (ja) 2012-10-25 2018-07-06 ミニプロモーターカセットを含むレトロウイルスベクター
JP2020136906A Pending JP2021006031A (ja) 2012-10-25 2020-08-14 ミニプロモーターカセットを含むレトロウイルスベクター

Country Status (6)

Country Link
US (1) US11065311B2 (cg-RX-API-DMAC7.html)
EP (2) EP2909324B1 (cg-RX-API-DMAC7.html)
JP (3) JP6419706B2 (cg-RX-API-DMAC7.html)
CN (1) CN104884627A (cg-RX-API-DMAC7.html)
ES (1) ES2786051T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014066700A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6894236B2 (ja) 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
JP2018526007A (ja) * 2015-09-04 2018-09-13 トカジェン インコーポレーテッド ２ａペプチドを含む組換えベクター
MA43285A (fr) * 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
ES2959326T3 (es) * 2015-11-24 2024-02-23 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
GB2572716B (en) 2016-11-29 2022-06-22 Articure Co Ltd Gene Therapy Vector System and Prodrug Genes
MA49153A (fr) 2017-05-19 2021-03-24 Encoded Therapeutics Inc Éléments régulateurs à haute activité
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
GB201720948D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Plasmid system
EP3880829A4 (en) * 2018-11-13 2022-08-24 Denovo Biopharma LLC RECOMBINANT VECTORS INCLUDING GENES FOR BINDING DOMAINS AND SECRETABLE PEPTIDES
TWI883032B (zh) 2019-08-12 2025-05-11 中國大陸商北京恩瑞尼生物科技股份有限公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
WO2021154455A1 (en) * 2020-01-30 2021-08-05 Purdue Research Foundation Ligand-mediated delivery of therapeutic proteins and the uses thereof
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
US20250243277A1 (en) 2021-10-07 2025-07-31 Avacta Life Sciences Limited Pd-l1 binding affimers
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
AU2023262112A1 (en) 2022-04-29 2024-10-31 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
CN116334010B (zh) * 2023-05-30 2023-08-29 中义(北京)健康研究院 一种重组单纯疱疹病毒及其制备方法和应用
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
DE68921034D1 (de) 1988-09-27 1995-03-23 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes HIV-I-Provirus und ein heterologes Gen enthält.
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
JP3378962B2 (ja) 1991-08-07 2003-02-17 アンダースン，ダブリュー．，フレンチ 内部リボソームエントリー部位を含むレトロウイルスベクター
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
CA2148934C (en) 1992-11-09 2005-08-02 French W. Anderson Targetable vector particles
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
CA2160034C (en) 1993-04-06 2005-09-06 Maribeth V. Eiden Gibbon ape leukemia virus-based retroviral vectors
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
US20030157070A1 (en) 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
EP2017337A1 (en) 1995-04-27 2009-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
GB9604354D0 (en) 1996-02-29 1996-05-01 Isis Innovation Targeting adapters
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
ATE397660T1 (de) 1996-08-16 2008-06-15 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
US6025192A (en) 1996-09-20 2000-02-15 Cold Spring Harbor Laboratory Modified retroviral vectors
AU731553B2 (en) 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP1003767A4 (en) 1997-05-30 2003-01-02 Human Genome Sciences Inc TR10 RECEPTOR OF HUMAN TUMOR NECROSIS FACTOR
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
AU1334999A (en) 1997-10-20 1999-05-10 Universita Degli Studi Di Padova A packaging cell line producing siv-pseudotyped mlv
FR2773561A1 (fr) 1998-01-15 1999-07-16 Centre Nat Rech Scient Utilisation d'une sequence riche en proline pour augmenter le caractere fusogenique d'enveloppes de retrovirus
US6451304B1 (en) 1998-03-09 2002-09-17 The Regents Of The University Of California Method for retrovirus vector production by separated gag and pol expression
CA2327444A1 (en) 1998-04-29 1999-11-04 Oklahoma Medical Research Foundation Construction of retroviral producer cells from adenoviral and retroviral vectors
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
GB9810752D0 (en) 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
AU4089899A (en) 1998-05-20 1999-12-06 University Of Tennessee Research Corporation, The Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP1115290B1 (en) 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
GB0122803D0 (en) 2001-09-21 2001-11-14 Oxford Biomedica Ltd Vector
US6576463B1 (en) 1999-01-15 2003-06-10 The Regents Of The University Of California Hybrid vectors for gene therapy
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
EP1059356B1 (en) 1999-06-09 2005-11-02 Universite Pierre Et Marie Curie Paris Vi Replicating retroviral constructs, preparation and uses for gene delivery
EP1059357A1 (en) 1999-06-09 2000-12-13 Universite Pierre Et Marie Curie Paris Vi Replicating or semi-replicating retroviral constructs, preparation and uses for gene delivery
GB2368846B (en) * 1999-07-08 2004-08-25 Univ California Isolated Jaagsiekte retroviruses (JSRV), gene delivery vectors, and methods of use
US8163893B2 (en) 2006-02-15 2012-04-24 The Regents Of The University Of Caifornia Pseudotyped retroviral vectors and methods of use thereof
AU7521500A (en) 1999-11-30 2001-06-12 Novartis Ag Increased transgene expression in retroviral vectors having scaffold attachment region
US6322696B1 (en) 2000-02-25 2001-11-27 Gp Companies, Inc. Inlet filter for high pressure sprayer
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2002022663A2 (en) 2000-09-18 2002-03-21 Maxygen, Inc. Stress resistant retroviruses
GB0024550D0 (cg-RX-API-DMAC7.html) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US20030003565A1 (en) 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
WO2002061104A2 (en) 2001-01-30 2002-08-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Hybrid adenoviral vector
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
JP2004532039A (ja) 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
JP2002335965A (ja) 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
DE10143237A1 (de) 2001-09-04 2003-03-20 Icon Genetics Ag Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente)
CA2498591A1 (en) 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
FR2832424B1 (fr) 2001-11-20 2004-09-24 Genethon Iii Plasmide chimere comprenant un genome retroviral replicatif et utilisations
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US20030219410A1 (en) 2002-02-01 2003-11-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated to PODs
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
EP1511767B1 (en) 2002-05-17 2009-07-22 RetroVec ApS A purified polypeptide, isolated nucleic acids encoding said polypeptide, vectors and use thereof
US20040068762A1 (en) 2002-07-17 2004-04-08 Attar Ricardo M. Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements
WO2004022761A1 (en) 2002-09-03 2004-03-18 Oxford Biomedica (Uk) Limited Retroviral vector and stable packaging cell lines
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20080227736A1 (en) 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
US20070003522A1 (en) 2004-07-08 2007-01-04 Albritton Lorraine M Methods and compositions for improved retroviral gene and drug delivery
RU2007114111A (ru) 2004-11-04 2008-12-10 Пфайзер Продактс Инк. (Us) Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы
CN101065492A (zh) 2004-11-24 2007-10-31 纳诺非科特有限公司 病毒载体
US20060147429A1 (en) 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
WO2006127980A2 (en) * 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
WO2007036233A2 (en) 2005-09-30 2007-04-05 Zgene A/S Dekkera/brettanomyces cytosine deaminases and their use
JP5976986B2 (ja) 2005-10-01 2016-08-24 チャールズ スタウト， 調節可能な融合プロモーター
WO2007044483A2 (en) 2005-10-07 2007-04-19 President And Fellows Of Harvard College Attenuated vaccines for non-segmented negative sense rna viruses
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US8557971B2 (en) 2006-03-17 2013-10-15 Aarhus Universitet Chimeric viral envelopes
CA2649063C (en) 2006-05-02 2014-11-25 Luigina Romani Use of thymosin .alpha.1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection
DK2048955T3 (da) 2006-07-21 2013-09-02 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
WO2008151633A2 (en) 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
CA2724740C (en) 2008-06-30 2017-02-21 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
MX2011003039A (es) 2008-09-26 2011-08-15 Tocagen Inc Vectores de terapia genica y citosina deaminasas.
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102459616A (zh) 2009-06-17 2012-05-16 托卡根公司 复制型逆转录病毒载体的生产细胞
US8993837B2 (en) 2010-08-13 2015-03-31 Pioneer Hi-Bred International, Inc Chimeric promoters and methods of use
US9669049B2 (en) 2010-10-31 2017-06-06 Tocagen Inc. Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
KR101888391B1 (ko) 2014-09-01 2018-08-14 삼성전자 주식회사 음성 신호 관리 방법 및 이를 제공하는 전자 장치

Also Published As

Publication number Publication date
JP2018183155A (ja) 2018-11-22
EP2909324A4 (en) 2016-07-06
ES2786051T3 (es) 2020-10-08
EP2909324A1 (en) 2015-08-26
WO2014066700A1 (en) 2014-05-01
JP2021006031A (ja) 2021-01-21
EP2909324B1 (en) 2020-02-26
EP3623478A1 (en) 2020-03-18
JP2015533510A (ja) 2015-11-26
US11065311B2 (en) 2021-07-20
CN104884627A (zh) 2015-09-02
US20150273029A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
JP6419706B2 (ja) ミニプロモーターカセットを含むレトロウイルスベクター
ES2709481T3 (es) Vectores recombinantes
US20220195460A1 (en) Retroviral vector having immune-stimulating activity
US10407666B2 (en) Recombinant vectors
JP2018526007A (ja) ２ａペプチドを含む組換えベクター
JP2016526920A (ja) 最適化ａ−バルジを有する組換えベクター
US20160222412A1 (en) Recombinant vector with stabilizing a-loop

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180918

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181010

R150 Certificate of patent or registration of utility model

Ref document number: 6419706

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees